Stockscreener 앱 받기
4.08
1.69%
-0.07
시간 외 거래:
4.08
전일 마감가:
$4.15
열려 있는:
$4.18
하루 거래량:
1.03M
Relative Volume:
0.52
시가총액:
$405.75M
수익:
$98.99M
순이익/손실:
$-197.98M
주가수익비율:
-2.0383
EPS:
-2.0017
순현금흐름:
$-175.32M
1주 성능:
-0.73%
1개월 성능:
-28.67%
6개월 성능:
-48.35%
1년 성능:
-57.23%
1일 변동 폭
$4.02
$4.18
1주일 범위
$4.02
$4.57
52주 변동 폭
$4.02
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.08 | 412.71M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Northland Capital | Outperform |
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Robbins LLP Reminds SPRY Stockholders of the Pending - GlobeNewswire
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - accessnewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with ... - Black Hills Pioneer
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
Join Class Action to Recover Losses from ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASD - The National Law Review
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026 - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class ActionContact SueWallSt - PR Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire Inc.
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 - PR Newswire
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Class Action Lawsuit Filed: ARS Pharmaceuticals, Inc. (SPRY)Join by October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc.October 5, 2026 Deadline - ACCESS Newswire
Contact Levi & Korsinsky by October 5, 2026 to Join Class Action Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class Action - Barchart.com
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - TMX Newsfile
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky For Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026 - NewMediaWire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of ARS Pharmaceuticals Inc. to Contact the Firm Today! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
Recover Investment Losses: Class Action Initiated Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - morning-times.com
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline - Morningstar
SPRY Shareholders Have Opportunity to Lead ARS Pharmaceuticals In - The National Law Review
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds AR - The National Law Review
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026 - FinancialContent
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - PR Newswire
ARS Pharmaceuticals Inc (SPRY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - GlobeNewswire
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) SharesPurchased Between March and June 2026Should Contact the Shareholders Foundation - Business Wire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Reminds Investors of the Securities Fraud Class - GlobeNewswire
Richard Lowenthal to sell 35,000 ARS Pharma (SPRY) shares - Stock Titan
ARS Pharmaceuticals (SPRY) officer sold $250K in stock and plans more - Stock Titan
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):